Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Business Summary
Logo UCB
Engages in the research, development, and commercialization of pharmaceutical and biotechnology products

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.

It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.

The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Number of employees : 7 478 persons.
Sales per Businesses
20162017Delta
EUR (in Million)%EUR (in Million)%
Cimzia1,30731.3%1,42431.4% +8.95%
Vimpat814.0019.5%976.0021.5% +19.9%
Keppra (Including Keppra XR)724.0017.3%778.0017.2% +7.46%
Other310.007.4%---
Neupro302.007.2%314.006.9% +3.97%
Zyrtec (including Zyrtec-D/Cirrus)140.003.4%103.002.3% -26.43%
Xyzal107.002.6%104.002.3% -2.8%
Venlaflaxine XR90.002.2%---
Nootropil46.001.1%44.001% -4.35%
Briviact18.000.4%87.001.9% +383.33%
Other Products--324.007.2%-
Designated hedges reclassified to net sales--28.000.6%-
Sales per Regions
20162017Delta
EUR (in Million)%EUR (in Million)%
United States1,85144.3%2,06945.7% +11.78%
Europe328.007.9%322.007.1% -1.83%
Other Countries319.007.6%371.008.2% +16.3%
Other292.007%295.006.5% +1.03%
Germany290.006.9%319.007% +10%
Japan268.006.4%292.006.4% +8.96%
Spain162.003.9%175.003.9% +8.02%
France161.003.9%161.003.6% 0%
Italy154.003.7%141.003.1% -8.44%
Belgium33.000.8%37.000.8% +12.12%
Managers
NameAgeSinceTitle
Jean-Christophe Tellier-2011Chief Executive Officer & Executive Director
Evelyn du Monceau681984Chairman
Charl van Zyl, MBA512017Chief Operating Officer
Detlef Thielgen-2006Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich MD, PhD582006Chief Medical Officer & Executive Vice President
Dhavalkumar Patel, PhD-2017Chief Scientific Officer
Herman de Prins--Chief Information Officer
Norman J. Ornstein, PhD-2008Independent Director
Albrecht de Graeve632010Independent Director
Charles-Antoine Janssen-2001Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 194,505,658 116,968,013 60.1% 6,294,677 3.2% 60.1%
Shareholders
NameEquities%
Financière de Tubize SA 68,076,981 35.0%
Wellington Management Co. LLP 14,082,883 7.24%
UCB SA 6,428,833 3.31%
Capital Research & Management Co. (World Investors) 3,695,790 1.90%
The Vanguard Group, Inc. 3,154,134 1.62%
BlackRock Fund Advisors 2,637,700 1.36%
Norges Bank Investment Management 2,377,002 1.22%
Wellington Management International Ltd. 1,990,643 1.02%
Schroder Investment Management Ltd. 1,928,928 0.99%
Capital Research & Management Co. (Global Investors) 1,699,000 0.87%
Holdings
NameEquities%Valuation
UCB (UCB) 6,428,8333.31%506,545,431 USD
Dermira Inc (DERM) 1,841,2344.40%15,981,911 USD
Arix Bioscience PLC (ARIX) 3,869,9022.87%10,685,186 USD
Heidelberg Pharma AG (WL6) 1,131,1864.03%3,736,828 USD
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Euronext 100, PEA
Stock Exchange Codes
- Bloomberg Code :  UCB:BB
- Reuters Code :  UCB.BR
- Datastream Code :  B:UCB
Company contact information
UCB
allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium

Phone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : http://www.ucb.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
UCB1.42%15 172
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862
AMGEN7.07%123 415
ABBOTT LABORATORIES8.88%108 943
BAYER-5.82%105 076
GLAXOSMITHKLINE17.20%102 028
SANOFI-4.93%99 211
ELI LILLY AND COMPANY2.79%93 651
ASTRAZENECA5.04%89 738
BRISTOL-MYERS SQUIBB COMPANY-12.47%88 674
NOVO NORDISK A/S-13.74%86 122
ALLERGAN PLC5.79%59 401
CELGENE CORPORATION-23.88%57 819
SHIRE2.82%48 273
JIANGSU HENGRUI MEDICINE CO LTD48.77%44 661
TAKEDA PHARMACEUTICAL CO LTD-30.86%32 467
ASTELLAS PHARMA INC21.10%31 605
Connections : UCB
SCR-Sibelco NV
FBNet Belgium
The Belgische Commissie Corporate Governance
Wallon Institute for Life Lead Sciences
Hoechst Marion Roussel, Inc.
Flanders-China Chamber of Commerce
The Innovative Medicines Initiative
European Federation of Pharmaceutical Industries & Assns
U.S. Capitol Historical Society
The Campaign Legal Center
Telenet NV
Drum Major Institute
The Conference Board, Inc.
Belgian Luxembourg Chamber of Commerce for Russia & Belarus
Pharmaceutical Research & Manufacturers of America
Biotechnology Innovation Organization
Johann Wolfgang Goethe-Universität Frankfurt am Main
Telenet Group BVBA
Inflazome Ltd.
Concours Reine Elisabeth
Université Libre de Bruxelles
International Business Leaders Advisory Council
Kanyos Bio, Inc.
Anokion SA
KOIS India Investment Advisors Pte Ltd.
© 2018 People , Fundamentals and Ownership    © 2018 Cofisem